1. Supplementary Tables and Figures from MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
- Author
-
Peter M. Siegel, Keith T. Flaherty, Ian R. Watson, Thomas Hawthorne, Tibor Keler, Lynda Chin, Lawrence Kwong, Zhifeng Dong, Marco Biondini, Dennie T. Frederick, Matthew G. Annis, and April A.N. Rose
- Abstract
Supplementary Fig. S1. Heatmap of mRNA expression for individual melanosomal differentiation antigens and a MITF transcriptional signature using a published dataset of melanoma samples (2). Supplementary Fig. S2. GPNMB expression is induced in multiple BRAF-mutant cells in response to MAPK pathway inhibition. Supplementary Fig. S3. Gene expression of MITF and GPNMB in melanoma cells following MAPK pathway inhibition. Supplementary Fig. S4. Dabrafenib and Trametinib stimulate MITF nuclear localization. Supplementary Fig. S5. Correlation of MITF and GPNMB mRNA expression in melanoma samples from patients that were on-treatment or that progressed on therapy with MAPK pathway 7 inhibitors. RT-qPCR data for MITF and GPNMB was expressed as the ratio relative to pretreatment levels. Supplementary Fig. S6. Correlation between the expression of individual melanosomal genes with MITF mRNA expression in melanoma samples from patients that were on-treatment or that progressed on therapy with MAPK pathway inhibitors. RT-qPCR data for each gene and MITF was normalized to GAPDH and expressed as the ratio relative to pre-treatment levels. Supplementary Fig. S7. MAPK pathway inhibition results in elevated levels of soluble GPNMB released from melanoma cells. Table S1: Clinical characteristics of patients biopsied for evaluation of MITF and GPNMB mRNA expression Table S2: Correlation coefficients between individual gene expression and MITF or a MITF Signature Table S3: Complete Responses Following Trametinib Treatment in Cohorts Injected with A375 or WM-2664 Melanoma Cells. Table S4: List of Primers for RT-qPCR Analyses
- Published
- 2023